Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic)
- Development stage
- Unknown
- Lead developer
- NeuroVita Clinic
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intrathecal, Subcutaneous
01
Overview
This personalized immunotherapy regimen, developed by the NeuroVita Clinic, is designed for the treatment of brain metastases originating from lung cancer. The therapy utilizes a multi-component approach consisting of a dendritic cell vaccine (DV), allogeneic haploidentical hematopoietic stem cells (HSCs), and cytotoxic lymphocytes (CTLs). The dendritic vaccine is prepared using tumor-specific antigens derived from the patient's own tumor sample to prime the immune system. Allogeneic HSCs are harvested from a closely related donor and administered intrathecally to provide immune modulation and potentially a graft-versus-tumor effect. CTLs are obtained from the patient's peripheral blood following DV administration and are used to directly target and eliminate tumor cells and tumor stem cells. The regimen aims to convert acute, lethal neuro-oncological processes into chronic, manageable conditions by regulating the effector functions of tumor stem cells.
- Other names
- Personalized Immunotherapy of Brain Metastases From Lung CancerProteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer
02
Targets
pMHC (Peptide-MHC complex family)MiHA (Minor histocompatibility antigen)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic).